Clinical trials: Smoking Addiction
Nicotine Addiction
Pharmacogenetics of Nicotine Addiction Treatment
The purpose of this research program is to understand how a biomarker called the "nicotine metabolite ratio" (also referred to as NMR) may influence a smoker's ability to quit smoking.
- Trial name
- NCT01314001
- Testing
- Varenicline, Transdermal Nicotine
- Where
- 4 sites in United States, Canada
- Volunteers
- 1,246 people
- Sponsor
- University of Pennsylvania
Nicotine Dependence, Nicotine Withdrawal
Progesterone and Brain Imaging Study
Male and female smokers were recruited to undergo 2 phases of smoking cessation. Each phase was 4 days long and involved 3 brain-imaging scans, blood draws and an intervention involving progesterone or a matched placebo.
- Trial name
- NCT01954966
- Testing
- Progesterone
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Nicotine Addiction
Effect of Galantamine on Smoking Abstinence
This is a preliminary open-label study to determine whether a medication called galantamine (Brand Name: Razadyne) will help smokers quit and whether it reduces cognitive problems that smokers experience during a quit attempt.
- Trial name
- NCT01548638
- Testing
- Galantamine ER
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Pennsylvania
Smoking Cessation, Nicotine Addiction
Nicotine Receptor Levels and Smoking Cessation
The investigators propose to use positron emission tomography (PET) imaging to determine whether nicotinic receptor availability at pretreatment predicts smoking cessation success.
- Trial name
- NCT01788943
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania